Symptoms and General Pathology

All Conditions

Infections

Musculoskeletal Diseases

Rare Diseases

Necrosis

Spondylitis

Spondylarthritis

Spondylitis, Ankylosing

Communicable Diseases

Bone Diseases

Bone Diseases, Infectious

Spinal Diseases

Arthritis

Joint Diseases

Axial Spondyloarthritis

Spondylarthropathies

Ankylosis

Spondylarthropathy

All Drugs and Chemicals

Anti-Inflammatory Agents

Antirheumatic Agents

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Adalimumab

Tumor Necrosis Factor Inhibitors

IBI303 40mg administered subcutaneously every other week, 12cycles

Adalimumab 40mg administered subcutaneously every other week

IBI303

Huji Xu

Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)

Adults patients with active ankylosing spondylitis (AS) were randomized in a 1:1 ratio to receive treatment with adalimumab 40 mg every other week (eow) or IBI303, given subcutaneously (SC), in the 24-week double-blind (DB) phase. Randomized participants received one SC injection of the appropriate DB study medication (adalimumab 40 mg or IBI303) at Week 0 and then eow until Week 22. A follow-up visit occurred 70 days(Week 32) after the last dose of study drug to obtain information on any ongoing or new adverse events (AEs).

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Monoclonal Antibody Against Human Tumor Necrosis Factor-α (IBI303) Compared to Adalimumab in Patients With Active Ankylosing Spondylitis

Innovent Biologics (Suzhou) Co. Ltd.

Spots Global Cancer Trial Database for as

Every month we try and update this database with for as cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for as

Every month we try and update this database with for as cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for as cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.